NCT00479128View on ClinicalTrials.gov

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 28, 2006

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Solid TumorUrethral Cancer
Interventions
DRUG

Bortezomib

Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds

DRUG

Gemcitabine

Starting dose: 225 mg/m\^2 IV Up to 90 Minutes

DRUG

Doxorubicin

Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER